Abstract
We investigated serum levels of interleukin-6 (IL-6), interferon-gamma (IFN-γ), and tumor necrosis factor alpha (TNFα) from patients with systemic lupus erythematosus (SLE) and its various clinical manifestations of disease and from patients with rheumatoid arthritis (RA) and other rheumatic diseases. The serum levels of IL-6 and IFN-γ were highly elevated from patients with SLE associated with lymphadenopathy (LN) or nephrotic syndrome (NS). On the contrary, the serum levels of TNFα were elevated from most patients with SLE associated with thrombocytopenia (TP). However, serum levels of TNFα were in the normal range from patients with SLE associated with NS, LN, or central nervous system disease. Of interest, patients with SLE associated with humoral immunodeficiency disorder, hypogammaglobulinemia, had highly elevated levels of serum IL-6. The concanavalin A-stimulated mononuclear cells (MNC) of patients with SLE associated with TP secreted highly elevated levels of TNFα compared to other patient groups. We suggest that abnormal production of various cytokines in SLE is an intrinsic defect of MNC and the immune system that may be the key element for a variety of clinical manifestations of this disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Dinarello CA, Mier JW: Current concepts, lymphokines. N Engl J Med 317:940–945, 1987
Beutler B, Cerami A: The biology of cachectin/TNF—a primary mediator of the host response. Annu Rev Immunol 7:625–655, 1989
Kishimoto T: The biology of interleukin-6. Blood 74:1–10, 1989
Sneller MC, Strober W: Abnormalities of lymphokine gene expression in patients with common variable immunodeficiency. J Immunol 144:3762–3769, 1990
Schattner A, Lachini M, Livnen A, Pras M, Hahn T: Tumor necrosis factor in familial mediterranean fever. Am J Med 90:434–438, 1991
Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinberg JR: Elevated levels of endogenous IL-6 in systemic lupus erythematosus: A putative role in pathogenesis. J Immunol 147:117–123, 1991
Helfgott DC, Tatter SB, Santhanam U, Clarick RM, Bhardwaj N, May T, Sehgal PB: Multiple forms of IFN-B2/IL-6 in serum and body fluids during acute bacterial infection. J Immunol 142:948–953, 1989
Clark IA, Cowden WB, Butcher GA, Hunt NH: Possible role of tumor necrosis factor in the pathology of malaria. Am J Pathol 129:192–199, 1987
Barral-Netto M, Badaro R, Almeida R, Santos S, Badaro F, Falcoff R: Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J Infect Dis 163:853–857, 1991
Akocer-Varela J, Aleman-Hoey D, Alarcon-Segovia D: Interleukin-1 and interleukin-6 are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T cell activation markers. Lupus 1:111–117, 1992
Bhardwaj N, Santhanam U, Lau L, Tatter S, Ghrayed J, Rivelis M, Steinman R, Sehgal P, May L: IL-6/IFN-B2 in synovial effusion of patients with rheumatoid arthritis and other arthritides. Identification of several isoforms and studies of cellular sources. J Immunol 143:2153–2159, 1989
Schur PH, Sandson J: Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 9:533–538, 1968
Smith HR, Steinberg AD: Autoimmunity—a perspective. Ann Rev Immunol 1:175–189, 1983
Tsokos GC, Margrath IT, Balow JE: Epstein-Barr virus induces normal B cell responses but defective suppressor T cell response in patients with systemic lupus erythematosus. J Immunol 131:1797–1801, 1983
Raziuddin S, Nur MA, Al-Wabel AA: Selective loss of the CD4+ inducers of suppressor T cell subsets (2H4+) in active systemic lupus erythematosus. J Rheumatol 16:1315–1319, 1989
Raziuddin S, Danial HB, Kelley M: OKT4 T cell abnormality in patients with systemic lupus erythematosus: HLA-DR antigen expressions. Clin Immunol Immunopathol 48:42–49, 1988
Fauci AS, Steinberg AD, Haynes BF, Whalen G: Immunoregulatory aberration in systemic lupus erythematosus. J Immunol 121:1473–1479, 1978
Campen DH, Horwitz DA, Quismorio FP, Ehresmann GR, Martin WJ: Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arth Rheum 31:1358–1364, 1988
Wilson JG, Fearon DT: Altered expression of complement receptors as a pathogenetic factor in systemic lupus erythematosus. Arth Rheum 27:1321–1327, 1984
Morimoto C, Reinherz EL, Distaso JA, Steinberg AD, Schlossman SF: Relationship between systemic lupus erythematosus T cell subsets, anti-T cell antibodies and T cell functions. J Clin Invest 73:689–700, 1984
Raziuddin S, Al-Janadi MA, Al-Wabel AA: Soluble interleukin-2 receptor levels in serum and its relationship to T cell abnormality and clinical manifestations of the disease in patients with systemic lupus erythematosus. J Rheumatol 18:831–836, 1991
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arth Rheum 25:271–1277, 1982
Arnett FC, Edworthy S, Block DA,et al.: The 1987 revised ARA criteria for rheumatoid arthritis. Arth Rheum 30:317, 1987
Talal N, Moutsopoulos HM, Kasan S: Sjogren's Syndrome. Heidelberg, Springer-Verlag, 1987
Bird HA, Esselinck W, Dixon AS, Mowat AG, Wood PHN: An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 38:434–439, 1979
Raziuddin S, Al-Janadi MA, Al-Wabel AA: T cell receptor alpha/beta chain-CD3 protein complex defect in systemic lupus erythematosus. T cell function. Am J Med 1992 (in press)
Scuderi P, Sterling K, Lam K, Finley P, Ryan K, Ray C, Peterson E, Slymen D, Salmon S: Raised serum levels of tumour necrosis factor in parasitic infections. Lancet 2:1364–1365, 1986
Tsokos GC, Smith PL, Balow JE: Development of hypogammaglobulinemia in a patient with systemic lupus erythematosus. Am J Med 81:1081–1084, 1986
Raziuddin S, Danial HB: OKT4+ T cell deficiency and an association of immunoglobulin deficiency in systemic lupus erythematosus. Clin Exp Immunol 72:466–469, 1988
Raziuddin S, Nur MA, Al-Janadi MA: CD4+ T lymphocyte deficiency and function in systemic lupus erythematosus and rheumatoid arthritis. Arth Rheum 33:1864–1865, 1990
Warrington RJ: B cell differentiation factor production in systemic lupus erythematosus. J Rheumatol 15:55–58, 1988
Abdou NI, Sagawa A, Rascual E, Habert J, Sadeghee S: Suppressor T cell abnormality in idiopathic systemic lupus erythematosus. Clin Immunol Immunopathol 6:192–199, 1976
Wolf RE, Brelsford WG: Soluble interleukin-2 receptors in systemic lupus erythematosus. Arth Rheum 31:729–735, 1988
Linker-Israeli M, Bakke AC, Kitridou RC, Gendler S, Gillis S, Horwitz DA: Defective production of interleukin-1 and interleukin-2 in patients with systemic lupus erythematosus. J Immunol 130:2651–2655, 1983
Houssiau FA, Devogelaer J-P, Van Damme J, Deuxchaisnes C, Van Snick J: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arth Rheum 31:784–788, 1988
Firestein GS, Alvaro-Garcia JM, Maki R: Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 144:3347–3353, 1990
Dasgupta B, Panayi GS: Interleukin-6 in serum of patients with polymalgia rheumatica and giant cell arteritis. Br J Rheumatol 29:456–458, 1990
Linker-Israeli M: Cytokine abnormalities in human lupus. Clin Immunol Immunopathol 63:10–12, 1992
Alcocer-Varela J, Aleman-Hoey D, Alarcon-Segovia D: Interleukin-1, interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlates with local late T-cell activation markers. Lupus 1:111–117, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Al-Janadi, M., Al-Balla, S., Al-Dalaan, A. et al. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 13, 58–67 (1993). https://doi.org/10.1007/BF00920636
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00920636